These results demonstrate the differential effect of CXCR4 antagonists on CD19-mediated activation signals in lymphoma cells and warrant further improvement in the combinatorial efficacy of CD19 mAb-induced ADCC and enhanced migration. The gene discussed is CXCR4; the disease is lymphoma.